Country

Clinical trials in Canada

Active obesity and GLP-1 studies with at least one location in Canada.

158active studies

82recruiting now

41countries represented

1,498largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

Semaglutide for Smoking Cessation in Patients With Diabetes

Diabetes Mellitus, Type 2, Nicotine AddictionCondition

Semaglutide, Nicotine replacementTreatment

Canada1 locations

Ottawa Heart Institute Research CorporationSponsor

Updated 2026-09-08 · NCT07059377See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 1

A Study to Evaluate ALN-6222 in Participants With Obesity

ObesityCondition

ALN-6222, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-09-03 · NCT07624071See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

Overweight, ObesityCondition

UBT251, Oral contraceptiveTreatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07710729See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 1, Phase 2

A Study to Evaluate ALN-2232 in Participants With Obesity

ObesityCondition

ALN-2232, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-12 · NCT07463846See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver DiseaseCondition

Metabolic surgery, Incretin-Based TherapyTreatment

Brazil, Canada22 locations

The Cleveland ClinicSponsor

Updated 2026-07-31 · NCT06374875See eligibility →

Recruiting nowNot applicable

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Type 2 Diabetes, ObesityCondition

Intervention not listedTreatment

Canada1 locations

University of AlbertaSponsor

Updated 2026-07-17 · NCT07272837See eligibility →

Recruiting nowNot applicable

Incretin-based Therapies, Nutrition, and Physical Activity

Obesity & Overweight, Cardiometabolic ConditionsCondition

Intervention, Incretin-Based TreatmentTreatment

Canada2 locations

Laval UniversitySponsor

Updated 2026-07-16 · NCT07409831See eligibility →

Recruiting nowNot applicable

Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources

PreDiabetes, Diabetes Mellitus, Type 2Condition

Keto-SAT, Keto-CANTreatment

Canada1 locations

University of AlbertaSponsor

Updated 2026-07-16 · NCT05681468See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowPhase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07339423See eligibility →

Recruiting nowNot applicable

Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control

Diabetes Mellitus, Type 2, ObesityCondition

Early (7:00 - 16:00) TRE, Mid (9:30 - 18:30) TRETreatment

Canada1 locations

University of TorontoSponsor

Updated 2026-06-30 · NCT06118931See eligibility →

Recruiting nowPhase 4

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

Obesity, Chronic Kidney DiseaseCondition

Semaglutide, Virtual Weight Management CoachingTreatment

Canada1 locations

Western University, CanadaSponsor

Updated 2026-06-29 · NCT06396416See eligibility →

Recruiting nowPhase 4

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Kidney Disease, Chronic, DiabetesCondition

Semaglutide PenTreatment

Canada2 locations

Unity Health TorontoSponsor

Updated 2026-06-26 · NCT07017270See eligibility →

Recruiting nowNot applicable

Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients

ObesityCondition

Head position for face mask ventilation during induction supine, Head position for face mask ventilation during induction head elevatedTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-06-17 · NCT06305273See eligibility →

Recruiting nowPhase 2

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Diabetic Kidney Disease, Type 1 DiabetesCondition

Semaglutide, PlaceboTreatment

Canada, United States4 locations

University of WashingtonSponsor

Updated 2026-06-02 · NCT05822609See eligibility →

Recruiting nowPhase 2, Phase 3

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

Type 1 Diabetes, Type 1 Diabetes MellitusCondition

Tirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM)Treatment

Canada, Switzerland4 locations

McGill University Health Centre/Research Institute of the McGill University Health CentreSponsor

Updated 2026-05-27 · NCT07284511See eligibility →

Recruiting nowNot applicable

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Obesity (Disorder), Obesity & OverweightCondition

Magnet System, SemaglutideTreatment

Canada1 locations

GT Metabolic Solutions, Inc.Sponsor

Updated 2026-05-19 · NCT07317115See eligibility →

Recruiting nowNot applicable

Egg Intake, Metabolic Outcomes and Choline Levels

Obesity and Obesity-related Medical ConditionsCondition

3 whole eggsTreatment

Canada1 locations

University of GuelphSponsor

Updated 2026-05-12 · NCT06687122See eligibility →

Recruiting nowNot applicable

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

Chronic Kidney Disease in Type 2 Diabetes, Obesity & OverweightCondition

Intervention not listedTreatment

Canada1 locations

University of AlbertaSponsor

Updated 2026-05-11 · NCT07187830See eligibility →

Recruiting nowPhase 2

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Kidney Transplant RecipientsCondition

Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mLTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2026-05-01 · NCT05938712See eligibility →

Recruiting nowPhase 2

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Overweight, ObesityCondition

UBT251, PlaceboTreatment

Canada, United States3 locations

Novo Nordisk A/SSponsor

Updated 2026-04-21 · NCT07395687See eligibility →

Recruiting nowPhase 2

Transpulmonary Assessment for Individualized Lung Optimization in Obese Patients

Respiratory FailureCondition

Esophageal pressure-guided PEEP titration, Standard care PEEP managementTreatment

Canada2 locations

University of AlbertaSponsor

Updated 2026-04-13 · NCT07359261See eligibility →

Recruiting nowNot applicable

Acute Sauna Session and Glucose Control

Obesity & OverweightCondition

Infrared sauna session, Resting conditionTreatment

Canada1 locations

University of Prince Edward IslandSponsor

Updated 2026-04-09 · NCT07520929See eligibility →

Recruiting nowNot applicable

Acute and Chronic Effects of Obesity

Obesity & Overweight, Metabolism ChangesCondition

Weight lossTreatment

Canada2 locations

Concordia University, MontrealSponsor

Updated 2026-04-07 · NCT07515547See eligibility →

Recruiting nowPhase 4

Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

Intellectual Disability, Developmental DisabilityCondition

Metformin, PlaceboTreatment

Canada1 locations

Centre for Addiction and Mental HealthSponsor

Updated 2026-03-31 · NCT05744479See eligibility →

Recruiting nowNot applicable

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Prediabetes / Type 2 DiabetesCondition

AMPK Charge+®, AMPK Charge+® with semaglutideTreatment

Canada1 locations

QuickSilver ScientificSponsor

Updated 2026-03-16 · NCT07195994See eligibility →

Recruiting nowPhase 1

Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study

High Blood Sugar, High Blood PressureCondition

Egg White PowderTreatment

Canada1 locations

University of AlbertaSponsor

Updated 2026-03-13 · NCT06555393See eligibility →

Recruiting nowNot applicable

Effects of Cranberry on Gut and Metabolic Health

Overweight/Obesity, Metabolic SyndromeCondition

Cranberry beverage, Placebo beverageTreatment

Canada1 locations

Laval UniversitySponsor

Updated 2026-03-10 · NCT07460856See eligibility →

Recruiting nowPhase 1

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

ObesityCondition

INV-347Treatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-03-06 · NCT07153172See eligibility →

Recruiting nowNot applicable

The Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors

Dairy Consumption, Metabolic HealthCondition

Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study), Dairy (short-term study)Treatment

Canada2 locations

University of TorontoSponsor

Updated 2026-03-05 · NCT06879652See eligibility →

Recruiting nowNot applicable

Evaluation of Food Additive Contributions to Obesity: Pilot Study 1

Obesity (Disorder)Condition

Potassium sorbate one-time administration followed by washout then placebo one-time administration, Placebo one-time administration followed by washout then potassium sorbate one-time administrationTreatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-02-27 · NCT07437430See eligibility →

Recruiting nowNot applicable

Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial

Type 2 Diabetes, Overweight (BMI > 25)Condition

Time-restricted eating, Standard lifestyleTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-02-11 · NCT07272460See eligibility →

Recruiting nowPhase 3

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Obesity (Disorder), Weight ChangeCondition

Gradual dose reduction of semaglutide, Abrupt cessation of semaglutideTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-02-11 · NCT07294950See eligibility →

Recruiting nowPhase 4

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Obesity (Disorder)Condition

Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)Treatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-01-14 · NCT06852391See eligibility →

Recruiting nowNot applicable

Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery

Obesity, Obesity, MorbidCondition

Standard duodenal switch, Single-anastomosis duodenal switchTreatment

Canada1 locations

Laval UniversitySponsor

Updated 2025-12-08 · NCT05242835See eligibility →

Recruiting nowNot applicable

Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery

Obesity (Disorder), Obesity and Obesity-related Medical ConditionsCondition

Bariatric SurgeryTreatment

Canada, Mexico2 locations

Hospital General de México Dr. Eduardo LiceagaSponsor

Updated 2025-11-17 · NCT07229924See eligibility →

Recruiting nowPhase 3

Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

Obesity, Childhood, Insulin ResistanceCondition

Metformin 850 mg oral tablet bid, Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.Treatment

Canada1 locations

University of AlbertaSponsor

Updated 2025-11-17 · NCT04578652See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related countries

United States1,107 China326 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.